SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-003432 to MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)

MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)
Date: April 5, 2023 · CIK: 0001267813 · Accession: 0000000000-23-003432

AI Filing Summary & Sentiment

File numbers found in text: 333-271041

Date
April 5, 2023
Author
Not clearly detected
Form
UPLOAD
Company
MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)

Letter

United States securities and exchange commission logo April 5, 2023 Martha Manning, Esq. General Counsel Marinus Pharmaceuticals, Inc. 5 Radnor Corporate Center, Suite 500 100 Matsonford Rd Radnor, Pennsylvania 19087 Re:Marinus Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 31, 2023 File No. 333-271041 Dear Martha Manning: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen M. Nicolai, Esq.

Show Raw Text
United States securities and exchange commission logo
April 5, 2023
Martha Manning, Esq.
General Counsel
Marinus Pharmaceuticals, Inc.
5 Radnor Corporate Center, Suite 500
100 Matsonford Rd
Radnor, Pennsylvania 19087
Re:Marinus Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed March 31, 2023
File No. 333-271041
Dear Martha Manning:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Stephen M. Nicolai, Esq.